Loading organizations...
Loading organizations...

Real-World Data for Health Innovation
Segmed has raised $17.0M across 3 funding rounds.
Key people at Segmed.
Segmed was founded in 2019 by Martin Willemink (Co-founder) and Jie Wu (Founder).
Segmed has raised $17.0M in total across 3 funding rounds.
Segmed provides at-scale access to novel clinical data globally, offering millions of diagnostic-grade medical images to accelerate innovation and mature the evidence needs of life sciences and technology industry.
Our solutions allow you to access a Real World Data (RWD) network to facilitate rapid discovery and investigational capability of imaging data, development of early disease detection & prediction models, improved patient recruitment and reduced operating burden to access therapeutic data ecosystem.
Segmed was founded in 2019 by Martin Willemink (Co-founder) and Jie Wu (Founder).
Segmed has raised $17.0M in total across 3 funding rounds.
Segmed's investors include Advocate Health, iGan Partners, Blumberg Capital, Nina Capital.
Key people at Segmed.
Segmed is a health technology company specializing in providing scalable, global access to de-identified, real-world medical imaging data. Their platform aggregates millions of diagnostic-grade medical images from over 2,000 healthcare locations worldwide, enabling life sciences, medical device companies, AI developers, and researchers to accelerate innovation in diagnostics, therapeutics, and clinical trials[1][2][3]. Segmed’s mission is to transform healthcare outcomes by unlocking diverse, regulatory-grade imaging datasets that support AI model development, early disease detection, patient recruitment, and evidence generation, thereby reducing operational burdens and speeding healthcare innovation[1][3][4].
For an investment firm, Segmed represents a cutting-edge player in the health data and AI innovation sector, focusing on real-world data (RWD) with a strong emphasis on medical imaging. Its impact on the startup ecosystem lies in enabling faster, more efficient access to critical healthcare data, which is a bottleneck in medical AI and life sciences research. For a portfolio company, Segmed builds a proprietary data platform (Openda) that serves healthcare researchers, AI developers, pharmaceutical companies, and medical device manufacturers by solving the problem of fragmented, inaccessible imaging data at scale[3][4].
Founded in 2017 by a team of Stanford engineers and physicians, Segmed emerged from the founders’ vision to revolutionize medical imaging research and improve patient outcomes through data-driven innovation[4][6]. The idea originated from recognizing the challenges in accessing diverse, high-quality imaging data needed for AI and clinical research. Early traction included partnerships with major healthcare providers and raising significant funding rounds, including a $10.4 million Series A led by Toronto VC iGan Partners and Advocate Health, which helped expand their footprint in healthcare AI and life sciences[5][6].
Segmed rides the wave of the healthcare data revolution, where the explosion of electronic health records, medical imaging, genomics, and AI demands scalable, diverse, and compliant real-world data access[7]. The timing is critical as AI-driven diagnostics and therapeutics require vast, high-quality datasets to train and validate models, and regulatory bodies increasingly accept real-world evidence for approvals. Market forces such as rising healthcare digitization, AI adoption, and regulatory shifts favor platforms like Segmed that reduce data fragmentation and accelerate innovation. Segmed influences the broader ecosystem by enabling faster AI development, improving clinical trial design, and fostering collaboration between healthcare providers, researchers, and industry[1][3][7].
Looking ahead, Segmed is poised to deepen its role as a foundational infrastructure provider for medical imaging data in AI and life sciences. Trends shaping its journey include increasing demand for real-world evidence, synthetic patient data innovation, and multi-omics integration. Segmed’s continued expansion of its global network and enhancement of its platform capabilities will likely strengthen its influence in accelerating healthcare innovation and regulatory science. As the healthcare industry embraces data-driven approaches, Segmed’s ability to provide secure, diverse, and regulatory-grade imaging data will be a critical enabler of next-generation diagnostics and therapeutics[3][10].
In sum, Segmed’s unique focus on scalable, high-quality medical imaging data positions it at the intersection of healthcare, AI, and real-world evidence, making it a key player in transforming health innovation globally.
Segmed has raised $17.0M across 3 funding rounds. Most recently, it raised $10.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $10.0M Series A | Advocate Health, iGan Partners | Blumberg Capital, Nina Capital |
| Nov 1, 2022 | $5.0M Seed | Nina Capital | |
| Dec 1, 2020 | $2.0M Seed | Blumberg Capital | Nina Capital |